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A B S T R A C T
The aim of the present work is to develop rifampicin loaded phospholipid lipospheres con-
taining sulfphobutyl ether β-cyclodextrin andVitamin C for inhalation to test their potential
for deep lung delivery. The findings of the solid state characterization revealed the amor-
phous nature of the lipospheres.These exhibited a better flowability, an aerodynamic diameter
in the range of 1.76 to 3.99 μm. Moreover, the fine particle fraction and emitted dose was
found in the range of 68.84–83.73% and 80–93%, respectively. Moreover, lipospheres exhib-
ited enhanced/equivalent efficacy in vitro in H37Rv strain. Hence, the results show the potential
of lipospheres for pulmonary delivery of rifampicin.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Shenyang Phar-
maceutical University. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Tuberculosis (TB) is a chronic infectious disease caused by My-
cobacterium tuberculosis (MTB). According to World Health
Organization (WHO), 1.5 million people died from TB, includ-
ing 360,000 among people who were HIV-positive (WHO Global
Tuberculosis Report 2014) [1].Amajor paradigm shift in the treat-
ment of TB occurred with the introduction of rifampicin (RMP),
the last landmark drug introduced for TB treatment [2]. RMP is
the semi-synthetic hydrazine derivative of rifampicin B [3]. In
addition to bactericidal effect on MTB, it exhibits excellent late
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sterilizing action on semi-dormant organisms undergoing short
bursts of metabolic activity. However, some of the challenges
that this potent antibiotic faces include poor water solubility,
low oral bioavailability, relatively short biological half-life (1.5–
5 h) [3], induction of a prehepatic first-pass metabolism,
hepatotoxicity and adverse effects due to multiple doses [4].
Hence, conventional oral treatment of TB is not only long-
term [5] but also associated with disadvantages of side effects
and systemic toxic effects due to high doses [6].Vitamin C (Ascor-
bic acid) (AA) is a water soluble vitamin which is a known
antioxidant [7,8] and free radical scavenger [9]. AA has been re-
ported to modulate RMP-induced hepatotoxicity in vivo [10] and
of other drugmolecules as well [11,12].Moreover, due to the pres-
ence of high iron concentration, reactive oxygen species
production and DNA damage, AA has sterilizing action on MTB
in vitro [13]. Cyclodextrins (CDs) are macrocyclic oligosaccha-
rides composed of (α-1, 4)-linked α-L-glucopyranose units [14–16]
with a hollow hydrophobic interior and a hydrophilic outer
surface. Application of CD in pharmaceutical, food and cos-
metic industry is extensive because of its inexpensive and non-
toxic nature. In pharmaceutical industry, they have been
employed to enhance the drug aqueous solubility and thereby
enhance the oral bioavailability of the encapsulated drug [17–21].
However, natural CDs are associated with problems of limited
solubility and toxicity related issues. To address this problem,
alkyl moieties such as hydroxyalkyl or methyl on free hy-
droxyl groups of CD were introduced [15,22]. Sulphobutyl ether
β-cyclodextrin (SBE-β-CD) is a chemically modified β-CD, cyclic
hydrophilic oligosaccharide.Also, the solubility in water for SBE-
β-CD is significantly higher than the parent β-CD. Furthermore,
SBE-β-CD does not exhibit the nephrotoxicity associated with
β-cyclodextrin [8].Moreover, no cytotoxic effects of SBE-β-CD have
been reported [23].
Pulmonary delivery via inhalation is a common technique
of drug administration to patients with a variety of lung dis-
eases [24,25]. This is the favoured route of administration of
drugs over both parenteral and oral route of drug administra-
tion. The principal advantages include reduced systemic side
effects and higher dose levels of the applicable medication at
the site of drug action. Unlike the oral route of drug admin-
istration, pulmonary inhalation is not subject to first-pass
metabolism. Administration of drugs to the lungs via the
inhaled route offers rapid onset of action, high local concen-
tration by direct delivery to the airways and hence high thera-
peutic ratio [26,27]. However, the airway geometry of the lung
poses a challenge for delivery into the alveoli. For effective de-
livery deep into the lung, the particle size should be between
1 and 5 μm [28], with mass median aerodynamic diameter
(MMAD) and geometric standard deviation (GSD) of aerosol-
ized particles. Particles above 5 μm are likely to be deposited
in the upper respiratory tract while particles below 1 μm could
be exhaled during expiration [29].
Therefore, the aim of this study was to evaluate RMP-
loaded dry powder formulation containing sulphobutylether
β-cyclodextrin (SDRPL-CD),Vitamin C (SDRPL-AA) and combi-
nation of both SBECD and AA (SDRPL-Comb). RMP has
previously shown interesting potential for treating pulmo-
nary TB infection via inhalation [4,30,31] and was chosen in
this report as a model molecule. The reports are not available
for inhaled phospholipid based lipospheres of RMP containing
sulphobutylether β-cyclodextrin andVitamin C along with the
in vitro antimycobacterial efficacy and aerosol performance
studies.
2. Materials and methods
2.1. Materials
RMP was obtained as a kind gift by Sandoz, Mumbai.The phos-
pholipid (Lipoid S-75) sample was kindly provided by Lipoid
Ludwigshafen, Germany. HPLC grade methanol was pur-
chased from Fisher Scientific, UK. Dichloromethane and other
chemicals were obtained from Loba Chemie, Mumbai, India.
Vitamin C was purchased from HiMedia, Mumbai. SBECD was
obtained as a kind gift sample from Cydex Pharmaceuticals
USA. All other chemicals were of analytical grade.
2.2. Methods
2.2.1. Preparation of spray dry powders
The spray drying open cycle system process was performed
using the BUCHI Mini Spray Dryer B-191 attached with
high-performance cyclone (BUCHI Labortechnik G, Flawil, Swit-
zerland). Co-spray dried particles (SDRPLs) were obtained by
spray drying organic solvent (dichloromethane) and aqueous
solutions RMP, PL and SBECD and AA, respectively. The feed
solution (3.5%w/w) was passed through a stainless steel 0.7 mm
diameter atomizing nozzle via a peristaltic pump at a flow rate
of 4 ml/min (pump rate 12%) employing atmospheric gas for
drying at a flow rate between 30 and 40 kg/h. A set inlet tem-
perature of 80 °C ± 2 °C (primary drying step) resulted in outlet
of 55 °C ± 3 °C (secondary drying step) with an aspirator rate
of 90%.The resultant dry powder particles were blown through
a high-performance cyclone separator and collected in the
sample container. Dry powder formulation was stored in glass
vials sealed with parafilm at room temperature.
2.2.2. Fourier transform infra red spectrometry
Fourier transform infra red spectrometry (FTIR) spectra of
samples were recorded with a FTIR spectrometer (Nicolet,
Impact 410, USA) employed with a denudated triglycine sul-
phate detector. The spectra were scanned in the region 450–
4000 cm−1 derived from 11 single average scans. Potassium
bromide pellet method was employed for the analysis.The data
were collected and analyzed using Omnic 5.1a software (Thermo
Nicolet, USA). These are similar conditions to those previ-
ously reported [5].
2.2.3. Thermal analysis
Thermograms were obtained on a Mettler Stare System (Mettler
Toledo, DSC 821e, Switzerland) using similar conditions pre-
viously reported in the literature [5]. Approximately 2–8 mg of
powder was carefully weighed into hermetic anodized alu-
minium DSC pans. An empty, hermetically sealed, anodized
aluminium pan was used as reference. Samples were heated
at a rate of 20 °C/min over a temperature range of 25 °C to
300 °C. Nitrogen gas at purge rate of 100 ml/min was used as
the purging gas.
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2.2.4. Crystallinity determination
The crystalline nature and non-crystallinity of samples were
examined using X-ray powder diffraction (XRPD) (Bruker axs
System,D8, Germany) with a slit detector Cu Kα radiation (35 kV,
20 mA) source.The scan range was 3 to 40° 2θ with a scan rate
of 10°/min at room temperature in a continuous scan mode.
The samples were placed on a horizontal quartz glass sample
holder plate.
2.2.5. Hot stage microscopy under cross polarizer
Hot stagemicroscopy (HSM) studies were performed under Leica
DMPL polarizedmicroscope (Leica MicrosystemsWetzlar GmbH,
Wetzlar Germany) equipped with Linkam LTS 350 hot stage.
Photomicrographs were captured using JVS colour video camera
and analyzed using Linksys32 software. The powder samples
were placed on glass slides with cover glass and heated at the
rate of 10 °C/min from 25 °C to 250 °C.
2.2.6. Morphology evaluation
Scanning electron microscopy (SEM) of the samples was evalu-
ated using SEM, equipped with a Hitachi S-3400 microscope
(Hitachi Ltd,Tokyo, Japan). Samples were placed on double sided
adhesive carbon tabs (Ted Pella, Inc., Redding, CA, USA), which
were adhered to aluminium stubs (Ted Pella, Inc.), and were
coated with gold thin film using a HummerVI sputtering system
from Hitachi. The coating process was operated at 25 mA dis-
charge current for 20 s.
2.2.7. Drug content and entrapment efficiency
RMP content in the spray dried powders was determined using
LCMS (Thermo Scientific, LTQ XL, Germany). For this analy-
sis, methanol and ammonium acetate buffer (10 mM, pH 3.4)
system was used in the ratio of 70:30. The column used for
chromatographic separation was Phenomenex C18 column
(250 mm × 4.6 mm, 5 μm) and flow rate was 1 ml/min at 4 °C
column temperature. The detection wavelength was 333 nm
and injection volume was 20 μl.
Entrapment efficiency (% EE) was calculated using the equa-
tion shown below:
% Drug content
Amountofdrug entrapped
Mass ofmicroparticles
= (1)
% EE
Actual drug loading
Theoretical drug loading
= ∗100 (2)
2.2.8. Bulk and tap density
For this, a known mass of powder was poured into a gradu-
ated cylinder, which is then tapped for defined number of times.
For calculation of tap and bulk densities, we noted the initial
volume and final volume (after tapping). Owing to the sample
size constraint, a 10 ml graduated cylinder was filled with
1000 mg of dry powder for testing and 1250 taps were applied
for this measurement. The static powder flow was deter-
mined by Carr’s compressibility index (CI).This was determined
by the following equation:
CI
Tapped density Bulk density
Tapped density
=
−
∗100 (3)
2.2.9. Powder flowability
For assessment of powder flowability, measurement of angle
of repose is the most frequently adopted method. Powder was
poured through a funnel to form a cone-shaped pile with an
angle, α, to the horizontal. The value of α was calculated by
measuring the height and radius of the pile formed. Powder
flowability is inversely proportional to the angle of repose i.e.
a large angle of repose is indicative of poor flow properties while
a small angle of repose indicates a free flowing powder [32].
Apart from angle of repose properties, Hausner ratio was also
determined.
Tan Height Baseα = ∗0 5. (4)
H R. . =
Tapped density
Bulk density
(5)
2.2.10. Specific surface area
To determine the surface area, approximately 100 mg of each
formulation were dried at 50 °C for 30 min under vacuum and
dead volume of sample cell was measured at room tempera-
ture. Nitrogen adsorption and desorption measurements were
performed using sample cells and empty reference cell im-
mersed in liquid nitrogen [33]. Eachmeasurement was repeated
twice to obtain the average surface area calculated by BET equa-
tion (Brunauer–Emmett–Teller) method.
Vm Va
P
P C
C
C
P
P
= −
⎛⎝ ⎞⎠ + − × ⎛⎝ ⎞⎠⎡⎣⎢
⎤
⎦⎥
0
1
1 1
0
(6)
S
VmNa
m
=
× 22 400,
(7)
2.2.11. In vitro antimycobacterial activity by BACTEC method
The antimycobacterial activity of SDRPL-CD, SDRPL-AA and
SDRPL-Comb formulation and RMP was tested on MTB H37Rv
strain (Tuberculosis Research Centre, Chennai, India). Briefly,
the bacteria were cultured in Middlebrook 7H9 liquid medium
(HiMedia, India) supplemented with 10% albumin, dextrose, and
catalase (ADC; HiMedia, India) to mid-log phase and then frozen
in aliquots at −70 °C until needed. We checked the purity of
culture by Ziehl–Neelsen staining (HiMedia, India). We dis-
solved the samples in dimethyl sulphoxide (DMSO) and filter
sterilized through 0.2 μm DMSO safe filters (PALL Life Sci-
ences) before testing. The BACTEC 460 TB system (Becton
Dickinson, USA) was employed to determine a growth index
(GI) of the MTB. GI is the quantitative measure of 14CO2 liber-
ated by metabolism of 14C-labelled substrate in a medium and
expressed in numbers on a scale from 0 to 999. Briefly, 0.1 ml
of samples were transferred to 12B BACTEC vials, in dupli-
cate for each sample/drug concentration, unless mentioned
otherwise, and incubated at 37 °C in 5% CO2 atmosphere. GI
was calculated daily under aerobic condition until in 1:100 con-
trols; a value greater than 30 was obtained. In order to
determine the per cent inhibition, undiluted control reading
was used. Appropriate positive and negative controls were also
included in the calculation. The growth inhibition was ex-
pressed as a ratio of GI of drug to the respective control vial.
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The per cent growth inhibition was calculated for each drug
concentration [34,35].
2.2.12. In vitro pulmonary deposition studies
Aerosol performance of SDRPL-CD, SDRPL-AA and SDRPL-
Comb formulation was assessed using an eight stage, nonviable
Anderson Cascade Impactor with a preseparator (Graseby-
Anderson,Atlanta, USA) operating at an airflow of 28.3 l/m [36].
To overcome the particle bounce and re-entrainment phenom-
enon, the impaction plates were coated with 1.5%w/v of HPMC
(4000 cps) gel in water. Five hydroxypropyl methylcellulose hard
capsules (Size 3; Quali-V®; Qualicaps® Inc,Whitsett, NC, USA)
were loaded with 20 mg of powder per capsule followed by ac-
tuation time of 10 s. The drug content deposited in individual
impaction plates was rinsed with methanol and subjected to
HPLC analysis. From the drug deposition data the emitted dose
(ED), fine particle fraction (FPF), mean median aerodynamic di-
ameter (MMAD) and geometric standard deviation (GSD) were
calculated [37] as follows:
Emitted dose ED
Initial mass in capsule
Final mass remaining in
%( ) = − capsules
Initial mass in capsules
× 100% (8)
Fine particlefraction FPF
Mass deposited on stage through
In
%( )
=
2 7
itial particle mass loaded into capsules
× 100% (9)
2.2.13. Statistical analysis
The values are reported as the mean ± SD.The minimum level
of significance was set at P < 0.05. All statistical analyses were
performed using the GraphPad Prism 5.0 software (Graph pad
software [CA, USA]).
3. Result and discussion
3.1. FTIR
The FTIR spectra of RMP, PL, PM, SBECD,AA, SDRPL-CD, SDRPL-
AA and SDRPL-Comb formulations are shown in Fig. 1 (upper
legend).The characteristic absorption peaks of RMP present at
1734 cm−1 (νC=O acetyl stretching) and 1566 cm−1 (νC=C stretch-
ing) in the physical mixture indicate the additive effect (Fig. 1C).
In the spectra of AA (Fig. 1D) and SBECD (Fig. 1E), the charac-
teristic peaks were observed at 3412 (νO—H bond) and 3221 cm−1
(νC—H bond) and 3394 (νO—H bond) and 1650 cm−1 (bending
vibration of νC=C), respectively. However, in the spectra of the
SDRPL formulations (Fig. 1F–H), the intensity of four charac-
teristic absorption peaks of RMP at 1655 cm−1 (νC=N asymmetric
stretching), 1566 cm−1 (νC=C stretching), 1252 cm−1 (νC—O—C—
ether group) and 1430 cm−1 (νC—N stretching) was changed.
These findings suggested possible inter-molecular interac-
tions between the components in the dry powder.
3.2. DSC
The thermograms of RMP, PL, SBECD,AA, PM, SDRPL-CD, SDRPL-
AA and SDRPL-Comb formulations are shown in Fig. 1 (lower
legend). The AA (Fig. 2A) and RMP (Fig. 1B) thermogram shows
an endothermic peak at 195 °C and 187–193 °C, which repre-
sents the melting point of AA and RMP samples, respectively.
There are two endothermic peaks in the thermogram of PL
(Fig. 1C) at 153 °C and 210 °C. The thermogram of PM (Fig. 1D)
shows that the endothermic peak corresponding to the melting
point of the AA is present but reduced. However, there was no
melting endothermic peak present in the SDRPL-CD, SDRPL-
AA and SDRPL-Comb formulations (Fig. 1F–H). Absence of these
characteristic endothermic peaks is an indication of the amor-
phous nature of the formulations [38,39].
3.3. PXRD
PXRD is the direct method for determination of basic struc-
ture information of a material. Crystalline behaviour of free
RMP, SDRPL-CD, SDRPL-AA and SDRPL-Comb formulations were
examined by studying its PXRD. As shown in Fig. 2, the PXRD
diffractogram pattern of RMP (Fig. 2A) and AA (Fig. 2H) shows
distinct sharp diffraction peaks (i.e. the presence of long range
molecular order), indicating its crystalline nature. Fig. 2B and
D presents the diffractogram pattern of PL which displayed
peaks at position 2° and 8° and halo pattern of SBECD, indi-
cating its amorphous nature while in diffractogram pattern of
PM (Fig. 2C), there are still reduced diffraction peaks.This could
be due to the presence of RMP and AA in the sample. However,
no such diffraction peaks were observed in the diffractogram
pattern of SDRPL formulations as displayed in Fig. 2E–G, in-
dicative of its non-crystallinity. Hence, based on the PXRD results
it is evident that SDRPL formulations are amorphous in nature
and are in agreement with DSC findings.
3.4. HSM
Photomicrographs of RMP, PL, PM, SDRPL-CD, SDRPL-AA and
SDRPL-Comb formulations are shown in Figs 3–8.The RMP mi-
crographs exhibited the birefringency (blue arrow) pattern
(Fig. 3A–E). Gradually, it diminishes as the temperature is in-
creased. This kind of pattern confirms the crystalline nature
of the RMP. In Fig. 4A–E, melting of the crystals (black arrow)
of RMP was observed by deformation of the crystals. On the
contrary, the micrographs of SDRPL-CD (Fig. 5A–E), SDRPL-AA
(Fig. 6A–E) and SDRPL-Comb (Fig. 7A–E) showed softening (black
arrow) of the particles. This is probably due to the amor-
phous nature of the SDRPL formulations following spray drying
process. Representative micrograph of SDRPL-CD is pre-
sented under the cross-polarizer light in Fig. 8A–E wherein
completely dark images that lack birefringency are present.The
softening and lack of birefringency pattern in the SDRPL for-
mulations is evident of their amorphous nature [5]. Overall, HSM
findings confirmed the amorphous nature of the formula-
tions.These results are in agreement with DSC and PXRD data.
3.5. SEM
Dry powder particles were successfully produced by using spray
drying technology. The shape and surface morphology of all
samples were visualized via SEM and displayed in Figs 9 and
10. The image shown in Fig. 9A confirms the irregular size and
morphology of RMP crystal, which is in agreement with PXRD
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analysis that showed the crystalline nature of RMP. Fig. 9B dis-
played the shrunk and irregular shape of PL.Moreover, in Fig. 9C
and D a spherical shape and cubic crystals are observed of SBECD
andAA, respectively.The PM (Fig. 10A) revealed presence of RMP
crystal along with SBECD and AA. SDRPL-CD, SDRPL-AA and
SDRPL-Comb (Fig. 10B–D) presented the formation of fine par-
ticles, indicated by the spherical morphology within the size
range of 1 μm to 5 μm, which shows the potential for delivery
to the lungs [32,40]. In conclusion, the particle size exhibited by
all the powder formulations was in the respirable range.
3.6. Powder characterization
The tapped density of spray dried formulations was similar for
all powders, and ranged between 0.26 ± 0.003 gcm−3 and
0.33 ± 0.005 gcm−3 (data not presented). The better aerosoliza-
tion of the formulation is associated with the lower powder
densities [41,42]. Carr’s Index, Angle of Repose and Hausner
ratio were used to provide a measure of the flow properties.
In Carr’s Index, a value less than 25% indicates good flowing
powder, whereas value greater than 25% indicates cohesive
flowing powder [43]. Carr’s Index values in the SDRPL-CD,
SDRPL-AA and SDRPL-Comb formulations varied from 11.7%
(excellent flowability) to 13.5% (good flowability).Moreover,Angle
of Repose and Hausner ratio of the spray dried formulations
were in the range of 31.8 ± 4 to 35.1 ± 3 and 1.03 ± 0.02 to
1.21 ± 0.05, respectively. Results of the powder characteriza-
tion were not significant (P > 0.05) with pure SDRPL formulation
without CD and AA (data not presented). Findings of these pa-
rameters further proved the good flowing behaviour of the
Fig. 1 – FTIR spectra (upper legend) of (A) Rifampicin, (B) Phospholipid, (C) Physical mixture, (D) Ascorbic acid, (E)
Sulphobutylether-β-cyclodextrin, (F) SDRPL-CD, (G) SDRPL-AA, and (H) SDRPL-Comb; DSC thermograms (lower legend) of
(A) Ascorbic acid, (B) Rifampicin, (C) Phospholipid, (D) Physical mixture, (E) Sulphobutylether-β-cyclodextrin, (F) SDRPL-CD,
(G) SDRPL-AA, and (H) SDRPL-Comb.
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powders. Hence, it can be concluded that the developed SDRPL
formulations were found to have potential for the pulmo-
nary delivery of poor-aqueous soluble drugs. Powder
characterization data are compiled in Table 1.
3.7. In vitro pulmonary deposition studies
In vitro pulmonary deposition study results of SDRPL-CD, SDRPL-
AA and SDRPL-Comb formulations after 28.3 l/m using the eight
Fig. 2 – PXRD diffractogram pattern of (A) Rifampicin, (B) Phospholipid, (C) Physical mixture,
(D) Sulphobutylether-β-cyclodextrin, (E) SDRPL-CD, (F) SDRPL-AA, (G) SDRPL-Comb and (H) Ascorbic acid.
Fig. 3 – HSM micrographs of Rifampicin under cross polarizer.
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Fig. 4 – HSM micrographs of Rifampicin under ordinary light.
Fig. 5 – HSM micrographs of SDRPL-CD under ordinary light.
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stage Anderson Cascade Impactor are shown in Table 2 and
Fig. 11. To investigate in vitro aerosol powder performance, we
used Size 3 HPMC capsules. Aerodynamic studies by Ander-
sen Cascade Impactor were then conducted on these
preparations that met the delivered dose specifications (>75%)
and showed a respirable fraction higher than 50%. Efficiency
of inhalation delivery system depends on particle size and par-
ticle size distribution which are considered as the critical factors
Fig. 6 – HSM micrographs of SDRPL-AA under ordinary light.
Fig. 7 – HSM micrographs of SDRPL-Comb under ordinary light.
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for deposition of particles in the alveolar region. An aerody-
namic particle size of 1–3 is required for optimal delivery to
the lung.
The efficiency of powder recovery was found to be >80%.
This indicated that the maximum amount of the drug was de-
livered by the device and small amount of the drug was retained
in the inhaler device. The per cent mass fraction of the aero-
solized particles from DPIs on the different stages of cascade
impactor is graphically presented in Fig. 11. Each bar repre-
sents the powder of certain sizes deposited on the stages of
the Anderson Cascade Impactor. Maximum FPF of 83.73 ± 2%
was observed with SDRPL-CD as compared to SDRPL-AA of
Fig. 8 – HSM micrographs of SDRPL-CD under polarized light.
Fig. 9 – Representative SEM image of (A) Rifampicin, (B) Phospholipid, (C) Sulphobutylether-β-cyclodextrin and (D) Ascorbic
acid.
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68.84 ± 4% and SDRPL-Comb of 69.01 ± 3% (Table 2). No signifi-
cant difference was observed between SDRPL-AA and SDRPL-
Comb. The per cent emitted dose was ranged from 80 ± 4% of
SDRPL-AA to 93 ± 1.5% for SDRPL-CD (Table 2). For efficient de-
livery of formulation to the lung, a combination of lower MMAD
and higher FPF is required [44].Therefore, higher the FPF greater
will be the deposition in the deeper lung resulting in enhanced
efficacy. SDRPL-CD was found to have a maximum FPF com-
pared to SDRPL-AA and SDRPL-Comb (Table 2). This could be
due to its less cohesive nature with lower surface area and van-
derWalls forces per unit mass of particles. In addition to this,
these particles tend to separate easily and provide maximum
fines. The mass median aerodynamic diameter (MMAD) and
geometric standard deviation (GSD) of SDRPL-CD, SDRPL-AA
and SDRPL-Comb were in the range of 1.76 ± 0.23 to 3.99 ± 0.13
and 2.11 ± 0.09 to 3.28 ± 0.1, respectively. Findings of the study
also revealed that SDRPL-CD displayed the best aerosol powder
performance among the various formulations in terms of ED,
FPF and MMAD. Deposition of SDRPL-AA formulation in the
cascade impactor was in the lower stages (stages 4 and 5) which
is most relevant for deep lung penetration [45], while in case
of SDRPL-CD and SDRPL-Comb, it was on stages 5 and 6 and
stages 3 and 5 of impactor, respectively.Thus, these results dem-
onstrated that the RMP loaded phospholipid lipospheres
incorporated with SBECD and AA formulations have poten-
tial for inhalation delivery.
3.8. In vitro antimycobacterial activity by BACTEC
method
All the three SDRPL-CD, SDRPL-AA and SDRPL-Comb formu-
lations were tested for antimycobacterial activity. All the
formulations exhibited enhanced/equivalent efficacy in vitro in
MTB H37Rv strain. DMSO was employed as the solubilizing
agent and its possible inhibitory effect on MTB growth was con-
sidered as well. The mechanism of action of RMP is to arrest
DNA-directed RNA synthesis of MTB by interacting with the
subunit of RNA polymerase [46]. The MIC values of RMP and
SDRPL formulations against MTB were found to be 0.05 and
Fig. 10 – Representative SEM image of (A) Physical mixture, (B) SDRPL-CD, (C) SDRPL-AA and (D) SDRPL-Comb.
Table 1 – Powder properties characterization.
Samples Angle of
Repose (°)a
Carr’s
Indexb
Hausner
ratioc
Specific
surface
area
SDRPL-CD 35.1 13.5 1.21 5.23
SDRPL-AA 32.4 12.3 1.11 6.11
SDRPL-Comb 31.8 11.7 1.03 6.21
a Angle of Repose: 25–30, Excellent; 31–35, good; 36–40, fair; 41–45,
passable; 46–55, poor; 56–65, very poor; >66, very-very poor.
b Carr’s Index: 5–12%, Excellent; 12–18%, good; 18–21%, fair; 21–
25%, poor, fluid; 25–32%, poor, cohesive; 32–38%, very poor; >40%,
extremely poor.
c Hausner ratio: 1.00–1.11, Excellent; 1.12–1.18, good; 1.19–1.25, fair;
1.26–1.34, passable; 1.35–1.45, poor; 1.46–1.59, very poor; >1.60, very-
very poor.
Table 2 – In vitro aerosol performance data of SDRPL
formulations.
Formulations %FPF %ED MMAD GSD
SDRPL-CD 83.73 93 1.76 2.11
SDRPL-AA 68.84 80 2.16 2.11
SDRPL-Comb 69.01 84 3.99 2.54
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0.005, 0.024, 0.028 μg/ml, respectively. Thus, SDRPL-CD formu-
lation exhibited significant (P < 0.001) lowest MIC value among
all the formulations. Also, in comparison to pure SDRPL
lipospheres, it exhibited two folds (0.005 μg/ml vs 0.01 μg/ml)
improved in vitro efficacy. Probably, this may be due to the
cyclodextrin–cholesterol complex formation and subse-
quently, removal of cholesterol from the membrane (Fig. 12).
It has been reported that MTB degrades the cholesterol to derive
Fig. 11 – In vitro aerosol performance as per cent deposition on each stage of Anderson Cascade Impactor (ACI).
Fig. 12 – Possible mechanism of cyclodextrin–cholesterol complex formation.
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the carbon and energy from this molecule for its growth [47–51].
As result of the cholesterol removal of membrane, fewer nu-
trients will be available for MTB and not able to survive in the
cells. On the other hand, SDRPL-AA has also shown improved/
equivalent efficacy in vitro but not as remarkable as SDRPL-
CD formulation. It is reported that sterilizing effect of the AA
on the MTB culture is due to its pro-oxidant effect which results
in increase in the ferrous ion concentration leading to ROS gen-
eration, alteration in lipid, imbalance in redox reaction and DNA
damage (Fig. 13). To our knowledge, this is the first time that
activity of a RMP loaded lipospheres formulation containing
SBECD and AA has been reported.
4. Conclusion
In the present study, a novel DPI system of rifampicin for in-
halation therapy was developed with the use of cyclodextrin
and vitamin C. Micronized spray dry powders prepared with
a spray drying technique showed suitable physicochemical and
powder flow properties for the inhalable dry powder. SDRPL-
CD formulation presented excellent in vitro antimycobacterial
efficacy and aerosol performance.The in vitro deposition study
using the cascade impactor also highlighted that spray dry
powders consistently deposited in deep lung regions. Overall,
the data from the study suggest an alternative option for in-
halation delivery of an antitubercular drug directly into the
lungs, which may enhance therapeutic efficacy and greatly
reduce adverse effects. The study establishes that rifampicin
can be successfully loaded into phospholipid lipospheres for
pulmonary delivery. Hence, it can be concluded that SDRPL for-
mulations have potential for better management in the
tuberculosis therapy.
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